Puerto Rico's Caribbean Imaging and Radiation Therapy Center Orders Elekta's New Versa HD System for Treatment of Cancer Patients
Linear accelerator is island's first Versa HD
PONCE, Puerto Rico, May 17, 2013 -- (Healthcare Sales & Marketing Network) -- Serving a region of 650,000 inhabitants in southern, central and western Puerto Rico, Caribbean Imaging and Radiation Therapy (C...
Devices, Oncology
Elekta, Versa HD, stereotactic, radiosurgery, radiotherapy
Devices, Oncology
Elekta, Versa HD, stereotactic, radiosurgery, radiotherapy
Thoratec Announces FDA Approval Of HeartMate II(R) Pocket Controller(TM)
PLEASANTON, Calif., May 17, 2013 -- (Healthcare Sales & Marketing Network) -- Thoratec Corporation (THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it has rec...
Devices, Cardiology, FDA
Thoratec, HeartMate II, Pocket Controller, HeartMate II LVAD
Devices, Cardiology, FDA
Thoratec, HeartMate II, Pocket Controller, HeartMate II LVAD
Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case
Genentech and Biogen Idec have filed for re-hearing in the United States
COPENHAGEN, Denmark, May 17, 2013 -- (Healthcare Sales & Marketing Network) -- Genmab A/S (GEN.CO) announced today that Genentech and Biogen Idec have filed for a re-hearing en ba...
Biopharmaceuticals, Litigation
Genmab, Genentech, Biogen Idec, GlaxoSmithKline, Arzerra
Biopharmaceuticals, Litigation
Genmab, Genentech, Biogen Idec, GlaxoSmithKline, Arzerra
Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013
NATICK, Mass., May 17, 2013 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris.
"We are pleased to present a particularly rich an...
Devices, Interventional Cardiology
Boston Scientific, NG PROMUS trial, Promus PREMIER, SYNERGY Stent
Devices, Interventional Cardiology
Boston Scientific, NG PROMUS trial, Promus PREMIER, SYNERGY Stent
New Study Shows Effect of Neupro(R) (Rotigotine Transdermal System) on Cardiovascular Measures in Patients with Restless Legs Syndrome
Data Showed Reduced Nocturnal Systolic Blood Pressure Elevations and Periodic Limb Movements During Sleep in Restless Legs Syndrome (RLS) Patients
First study of its kind will be presented at the Annual Scientific Meeting of the American Society of Hype...
Biopharmaceuticals
UCB , Neupro, Rotigotine, Restless Legs Syndrome
Biopharmaceuticals
UCB , Neupro, Rotigotine, Restless Legs Syndrome
InspireMD Announces Reimbursement Coverage for MGuard(TM) Coronary Embolic Protection Stent
More than 18 Million Brazilians have Reimbursable Access to MGuard EPS
BOSTON and TEL AVIV, Israel, May 16, 2013 -- (Healthcare Sales & Marketing Network) --InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader i...
Devices, Interventional, Cardiology, Reimbursement
InspireMD, MGuard, Embolic Protection, Coronary Stent
Devices, Interventional, Cardiology, Reimbursement
InspireMD, MGuard, Embolic Protection, Coronary Stent
Novelos Therapeutics Provides Product Pipeline Update
To Begin I-124-CLR1404 (LIGHT) Phase 2 Imaging Trial in Brain Cancer in Early 2014
Evaluating I-131-CLR1404 (HOT) Potential Phase 2 Indications and Trial Designs
To File CLR1502 (GLOW2) IND for Intraoperative Tumor Margin Illumination by End 2013
MADI...
Biopharmaceuticals
Novelos Therapeutics, I-124-CLR1404, I-131-CLR1404, radiotherapeutic
Biopharmaceuticals
Novelos Therapeutics, I-124-CLR1404, I-131-CLR1404, radiotherapeutic
NW Bio Initiates Phase III DCVax(R)-L Brain Cancer Trial In Europe: King's College Hospital In The UK Is First Site To Open
Up To 30 European Sites To Join 46 Active Sites In The US
BETHESDA, Md., May 16, 2013 -- (Healthcare Sales & Marketing Network) -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax®-L personalized immune therapies ...
Biopharmaceuticals, Oncology
Northwest Biotherapeutics, DCVax-L, personalized immune therapies, Glioblastoma
Biopharmaceuticals, Oncology
Northwest Biotherapeutics, DCVax-L, personalized immune therapies, Glioblastoma
St. Jude Medical Announces European Approval of 3-D Vessel Reconstruction Technology to Aid Physicians in Stent Placement
Next-generation system provides a real-time 360-degree panoramic view of the arteries in 3-D
ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--St. Jude Medical, Inc. (STJ), a global medical device company, today announced CE Mark approval of its ...
Devices, Interventional Cardiology, Regulatory
St. Jude Medical, ILUMIEN OPTIS, PCI Optimization System, FFR
Devices, Interventional Cardiology, Regulatory
St. Jude Medical, ILUMIEN OPTIS, PCI Optimization System, FFR
New Clinical Study Finds Masimo rainbow(R) Acoustic Monitoring(TM) Technology More Accurately, Precisely, and Reliably Detects Ventilatory Pauses in Post-Surgical Patients
Published in the June 2013 Issue of Anesthesia & Analgesia, Study Demonstrates that Acoustic Respiration Rate (RRa) is More Sensitive to Ventilation Changes than Capnometry
IRVINE, Calif., May 16, 2013 -- (Healthcare Sales & Marketing Network) -- Masi...
Devices, Monitoring
Masimo, Acoustic Respiration Rate, RRa, rainbow Acoustic Monitoring
Devices, Monitoring
Masimo, Acoustic Respiration Rate, RRa, rainbow Acoustic Monitoring
Colibri Heart Valve to Present Six Month Follow-up Results from First Clinical Use at Upcoming EuroPCR Meeting
BROOMFIELD, CO, May 16, 2013 -- (Healthcare Sales & Marketing Network) -- Colibri Heart Valve, LLC, a privately held medical device company, today announced that Dr. Pedro Urenya will present six month follow-up results from the first-in-human implantation...
Devices, Interventional Cardiology
Colibri Heart Valve, transcatheter aortic heart valve, TAVI system
Devices, Interventional Cardiology
Colibri Heart Valve, transcatheter aortic heart valve, TAVI system
Echo Therapeutics to Unveil Symphony(R) CGM System in Webcast
Demonstration coincides with Symphony's upcoming CE Mark pivotal trial
PHILADELPHIA, May 16, 2013 -- (Healthcare Sales & Marketing Network) -- Echo Therapeutics, Inc. (ECTE), a company developing its needle-free Symphony® CGM System as a non-invasi...
Devices, Endocrinology, Monitoring
Echo Therapeutics, Symphony CGM, continuous glucose monitor
Devices, Endocrinology, Monitoring
Echo Therapeutics, Symphony CGM, continuous glucose monitor
FANG(TM) Personalized Tumor Vaccine Stimulates Immune Response and More than Doubles Time to Recurrence in Patients with Advanced Stage Ovarian Cancer
Interim Phase II Data and Follow-Up Analysis of Phase I Data Presented at Annual Meeting of the American Society of Gene and Cell Therapy
DALLAS, May 15, 2013 -- (Healthcare Sales & Marketing Network) -- Today Gradalis, Inc. announced that FANG, the c...
Biopharmaceuticals, Personalized Medicine, Oncology
Gradalis, FANG, personalized cancer vaccine, cancer vaccine
Biopharmaceuticals, Personalized Medicine, Oncology
Gradalis, FANG, personalized cancer vaccine, cancer vaccine
MiE's PET SCINTRON Receives FDA Approval
The first and only hardware and software upgrade available for Siemens ECAT 47, ECAT HR+, and ECAT Accel PET systems
HOUSTON, May 15, 2013--(Healthcare Sales & Marketing Network)--Medical Imaging Electronics (MiE) and Nuclear Imaging Services (NIS) are ...
Devices, Radiology, Oncology, FDA
Medical Imaging Electronics, ECAT Scintron, positron emission tomography
Devices, Radiology, Oncology, FDA
Medical Imaging Electronics, ECAT Scintron, positron emission tomography
Tokai Pharmaceuticals Announces $35.5 Million Series E Financing
Financing Reflects Encouraging Clinical Progress with Galeterone in Prostate Cancer
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate canc...
Biopharmaceuticals, Oncology, Venture Capital
Tokai Pharmaceuticals, prostate cancer, galeterone, ARMOR2, CRPC
Biopharmaceuticals, Oncology, Venture Capital
Tokai Pharmaceuticals, prostate cancer, galeterone, ARMOR2, CRPC
Achillion Appoints Dr. David Apelian as Chief Medical Officer and Expands Clinical Operations Team
NEW HAVEN, Conn., May 15, 2013 -- (Healthcare Sales & Marketing Network) -- Achillion Pharmaceuticals, Inc. (ACHN) today announced the appointment of David Apelian, M.D., Ph.D., MBA, to the position of Executive Vice President and Chief Medical Officer, ef...
Biopharmaceuticals, Personnel
Achillion Pharmaceuticals
Biopharmaceuticals, Personnel
Achillion Pharmaceuticals
RaySearch Laboratories: RaySearch receives 510(k) clearance for RayStation(R) 3.5
STOCKHOLM--(Healthcare Sales & Marketing Network)--In March RaySearch Laboratories AB announced that version 3.5 of RaySearch's RayStation® treatment planning system had been released for clinical use. RaySearch has now received 510(k) clearance from t...
Devices, Oncology, FDA
RaySearch Laboratories, RayStation, treatment planning, radiotherapy
Devices, Oncology, FDA
RaySearch Laboratories, RayStation, treatment planning, radiotherapy
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
WAYNE, N.J., May 15, 2013 -- (Healthcare Sales & Marketing Network) -- Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III tri...
Biopharmaceuticals, Oncology
Bayer HealthCare Pharmaceuticals, Stivarga, regorafenib, liver cancer
Biopharmaceuticals, Oncology
Bayer HealthCare Pharmaceuticals, Stivarga, regorafenib, liver cancer
Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials
PARIS and TARRYTOWN, N.Y., May 15, 2013 -- (Healthcare Sales & Marketing Network) -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regen...
Biopharmaceuticals
Regeneron Pharmaceuticals, Sanofi, sarilumab, SARIL-RA, rheumatoid arthritis
Biopharmaceuticals
Regeneron Pharmaceuticals, Sanofi, sarilumab, SARIL-RA, rheumatoid arthritis
Zosano Pharma, Inc. Appoints Nandan Oza as Chief Operations Officer
FREMONT, Calif., May 14, 2013 -- (Healthcare Sales & Marketing Network) -- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today a key addition to its executive...
Biopharmaceuticals, Drug Delivery, Personnel
Zosano Pharma, ZP Patch
Biopharmaceuticals, Drug Delivery, Personnel
Zosano Pharma, ZP Patch

